Topoisomerase-I inhibitors in gynecologic tumors

Hematology/Oncology Clinics of North America

Volumn 13, Issue 1, 1999, Pages 43-61

  Haluska, P ^a   Rubin, E ^a   Verschraegen, C F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ADENOSINE TRIPHOSPHATE; CAMPTOTHECIN DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; GYRASE INHIBITOR; HELICASE; IRINOTECAN; MELPHALAN; PACLITAXEL; TOPOTECAN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DNA DRUG COMPLEX; DNA SUPERCOILING; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; GYNECOLOGIC CANCER; HUMAN; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; UTERUS CANCER;

EID: 0033044401     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70153-2     Document Type: Article

References (112)

1. M. Ando K. Eguchi T. Shinkai Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer Br J Cancer 76 1997 1494
2. D. Armstrong E. Rowinsky R. Donehower A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer Proceedings of the Annual Meeting of the American Society of Clinical Oncology 14 1995 A769
3. D.K. Armstrong S. O'Reilly M. Bookman A Phase I study of topotecan (t), cisplatin (c) and paclitaxel (p) in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group (GOG 9602) study Proceedings of the American Society of Clinical Oncology 34 1998 1351
4. O. Balat C. Verschraegen Topoisomerase I inhibitors in gynecologic cancers Expert Opinion in Investigational Drugs 4 1995 1217
5. P. Benedetti P. Fiorani L. Capuani Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine Cancer Res 53 1993 4343
6. A.K. Bharti M.O.J. Olson D.W. Kufe Identification of a nucleolin binding site in human topoisomerase I J Biol Chem 271 1996 1993
7. M. Bjornsti P. Benedetti G. Vigilanti Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin Cancer Res 49 1989 6318
8. T.G. Burke Z. Mi Preferential binding of carboxylate form of camptothecin by human serum albumin Annals of Biochemistry 212 1993 285
9. Z. Cao N. Harris J. Mendoza Alkyl esters 9-nitrocamptothecin: Synthesis, toxicity and anti-tumor activity Proceedings of the American Association for Cancer Research 39 1998 A2859
10. J.J. Champoux Mechanistic aspects of type-I topoisomerases N.R. Cozzarelli J.C. Wang DNA Topology and Its Biological Effects 1990 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY 217
11. J. Chang L.A. Dethlefsen L.R. Barley Characterization of camptothecin-resistant Chinese hamster lung cells Biochem Pharmacol 43 1992 2443
12. S. Chatterjee M.F. Cheng D. Trivedi Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines Cancer Communications 1 1989 389
13. S.F. Chen M.L. Rothenberg G. Clark Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro Proceedings of the American Association for Cancer Research 35 1994 A2174
14. Chevallier B, Lhomme C, Dieras V, et al: Phase II trial of CPT-11 in advanced cervical carcinoma. EORTC Early Drug Development Meeting, Corfu, Greece. June 21–24, 1995
15. G.J. Creemers G. Bolis G. Scarfone Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study J Clin Oncol 14 1996 3056
16. M.K. Danks C.L. Morton C.A. Pawlik Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11 Cancer Res 58 1998 20
17. S.D. Desai L.F. Liu D. Vazquez-Abad Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin J Biol Chem 272 1997 24159
18. R.E. Dickerson H.R. Drew B.N. Conner The anatomy of A-, B-, and Z-DNA Science 216 1982 475
19. R.E. Dickerson DNA structure from A to Z Methods Enzymol 211 1992 67
20. R.E. Dickerson The DNA helix and how it is read Sci Am 247 1983 94
21. M. Donato D. Gershenson J.T. Wharton Phase I study of high-dose alkylating agents and topotecan for advanced ovarian cancer Proceedings of the American Society of Clinical Oncology 34 1998 291
22. E. Eisenhauer P. Hoskins S. Beare Randomized phase II study of two schedules of topotecan in epithelial ovarian cancer (EOC) Proceedings of the Annual Meeting of the American Society of Clinical Oncology 16 1997 1249
23. W.K. Eng F.L. McCabe K.B. Tan Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content Mol Pharmacol 38 1990 471
24. A.M. Ferro B.M. Olivera Poly (ADP-ribosylation) of DNA topoisomerase I from calf thymus J Biol Chem 259 1984 547
25. J.M. Ford J.M. Yang W.N. Hait P-glycoprotein-mediated multidrug resistance: Experimental and clinical strategies for its reversal Cancer Treat Res 87 1996 3
26. X. Fu The superfamily of arginine/serine rich splicing factors RNA 1 1995 663 680
27. A. Fujimori W.G. Harker G. Kohlhagen Mutation of the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin Cancer Res 55 1995 1339
28. S. Gangloff J.P. McDonald C. Bendixen The yeast type I topoisomerase top3 interacts with Sgs1, a DNA helicase homolog: A potential eukaryotic reverse gyrase Mol Cell Biol 14 1994 8391
29. H. Ginisty F. Amalric P. Bouvet Nucleolin functions in the first step of ribosomal RNA processing EMBO J 17 1998 1476
30. B.C. Giovanella H.R. Hinz A.J. Kozielski Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin Cancer Res 51 1991 3052
31. B.C. Giovanella J.S. Stehlin M.E. Wall DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts Science 246 1989 1046
32. Gordon A. ten Bokkel Huinink W. Pooled analysis of patients (pts) with recurrent ovarian cancer (ROC) who were treated with topotecan (T) after progression or failure on first- or second-line platinum (PLAT) and paclitaxel (P) Proceedings of the Annual Meeting of the American Society of Clinical Oncology 16 1997 A1319
33. I.I. Gromova E. Kjeldsen J.Q. Svestrup Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I Nucleic Acids Research 21 1993 593
34. Gupta E. Toppmeyer D. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy Cancer Therapeutics 1998 in press
35. R.S. Gupta R. Gupta B. Eng Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I Cancer Res 48 1988 6404
36. M. Gutpa S. Fan Q. Zhan Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells Clinical Cancer Research 3 1997 1653
37. M.C. Haaz L.P. Rivory C. Riche The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms Naunyn Schmiedebergs Arch Pharmacol 356 1997 257
38. P. Haluska A. Saleem T.K. Edwards Interaction between the N-terminus of human topoisomerase I and SV40 T antigen Nucleic Acids Res 26 1998 1841
39. R. Hanai P.R. Caron J.C. Wang Human TOP3: A single copy gene encoding DNA topoisomerase II Proc Natl Acad Sci USA 93 1996 3653
40. R.P. Hertzberg M.J. Caranfa K.G. Holdern Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity J Med Chem 32 1982 15
41. H. Hochster L. Liebes J. Speyer Effect of prolonged topotecan infusion on topoisomerase I levels: A phase I and pharmacodynamic study Clinical Cancer Research 3 1997 1245
42. Y. Hsiang M. Lihou L. Liu Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin Cancer Res 49 1989 5077
43. Y. Hsiang L. Liu Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin Cancer Res 48 1988 1722
44. Y.H. Hsiang L.F. Liu M.E. Wall DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs Cancer Res 49 1989 4385
45. W.J. Jansen T.M. Hulscher J. van Ark-Otte CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein Br J Cancer 77 1998 359
46. C. Jaxel K.W. Kohn M.C. Wani Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity Cancer Res 49 1989 1465
47. E. Jonsson H. Fridborg K. Csoka Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients Br J Cancer 76 1997 211
48. F. Kanzawa Y. Sugimoto K. Minato Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non small lung cancer: Characterization and mechanism of resistance Cancer Res 50 1990 5919
49. R. Kapoor D.L. Slade A. Fujimori Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin Oncol Res 7 1995 83
50. U.N. Kasid B. Halligan L.F. Liu Poly(ADP-ribose)–mediated post-translational modification of chromatin-associated human topoisomerase I J Biol Chem 264 1989 18687
51. N.V. Koshkina J.C. Waldrep B.E. Gilbert Anticancer effect of liposomal 9-nitrocamptothecin aerosol delivery on human cancer xenograft models Proceedings of the American Association for Cancer Research 39 1998 1902
52. N. Kubota F. Kanzawa K. Nishio Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line Biochem Biophys Res Commun 188 1992 571
53. A.P. Kudelka D. Tresukosol C.L. Edwards Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 14 1996 1552
54. Y. Kwato M. Aonuma T. Hirota Intracellular roles of SN-38, a metabolite of the camptothecin derivative, CPT-11, in the antitumor effect of CPT-11 Cancer Res 51 1991 4187
55. E. Labourier F. Rossi I. Gallouzi Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor Nucleic Acids Res 26 1998 2955
56. Li X.-G. P. Haluska Y. Hsiang Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis Biochem Pharmacol 53 1997 1019
57. L. Liu J. Wang Supercoiling of the DNA template during RNA transcription Proc Natl Acad Sci USA 84 1987 7024
58. L.F. Liu DNA topoisomerase poisons as antitumor drugs Annu Rev Biochem 58 1989 351
59. Look KY, Blessing JA, Levenback C, et al: A phase II trial of CPT-11 in chemotherapy-naïve patients with recurrent squamous carcinoma of the cervix (SCC): A Gynecologic Oncology Group (GOG) Study. Proceedings of the Society of Gynecologic Oncology A134, 1998.
60. S. Lowe S. Bodis A. McClatchey p53 status and the efficacy of cancer therapy in vivo Science 266 1994 807
61. J. Ma M. Maliepaard K. Nooter Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line Br J Cancer 77 1998 1645
62. I. Madelaine S. Prost A. Naudin Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation Biochem Pharmacol 45 1993 339
63. N. Masumoto S. Nakano T. Esaki Inhibition of cis-diamminedichloroplatinum (II)–induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous cell carcinoma cells Int J Cancer 62 1995 70
64. D.S. Miller J.A. Blessing L.C. Kilgore A phase II trial of topotecan in patients with advanced, persistent or recurrent uterine leiomyosarcomas. A Gynecologic Oncology Group study Proceedings of the American Society of Clinical Oncology 34 1998 1421
65. I. Mitsui E. Kumazawa Y. Hirota A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo Jap J Cancer Res 86 1995 776
66. S.G. Morham K.D. Kluckman N. Voulomanos Targeted disruption of the mouse topoisomerase I gene by camptothecin selection Mol Cell Biol 16 1996 6804
67. H. Mori M. Sawairi N. Itoh Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines Anticancer Drugs 2 1991 469
68. K. Noda H. Sasaki K. Yamamoto Phase II trial of topotecan for cervical cancer of the uterus Proceedings of the Annual Meeting of the American Society of Clinical Oncology 15 1996 A754
69. T. Ohmori E.R. Podack K. Nishio Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2 Biochem Biophys Res Commun 192 1993 30
70. L. Paz-Ares P. O'Dwyer J. Cassidy Phase I clinical and pharmacokinetic study of a new topoisomerase inhibitor, GG211, given as a 72-hour continuous infusion Br J Cancer 71 1994 10
71. S. Plaxe R. Christen J. O'Quigley Phase I trial of IP topotecan Proceedings of the Annual Meeting of the American Society of Clinical Oncology 12 1993 A360
72. Y. Pommier G. Kohlhagen K.W. Kohn Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites Proc Natl Acad Sci USA 92 1995 8861
73. M.R. Redinbo L. Stewart P. Kuhn Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA Science 279 1998 1504
74. R.J.D. Reid H. Askari P. Fiorani Novel genes affecting DNA topoisomerase I poison sensitivity Proceedings of the American Association for Cancer Research 39 1998 a546
75. R.J.D. Reid E.A. Kauh M. Bjornsti Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast J Biol Chem 272 1997 12091
76. F. Rossi E. Labourier T. Forne Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I Nature 381 1996 80
77. E.K. Rowinsky L.B. Grochow C.B. Hendricks Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor J Clin Oncol 10 1992 647
78. E. Rubin P. Pantazis A. Bharti Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin J Biol Chem 269 1994 2433
79. E. Rubin V. Wood A. Bharti A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin Clinical Cancer Research 1 1995 269
80. E.H. Rubin T. Li P. Duan Cellular resistance to topoisomerase poisons Hait W.N. Drug Resistance 1996 Kluwer Academic Publishers Norwell, MA 243
81. J. Sekiguchi S. Shuman Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I Mol Cell Biol 1 1997 89
82. D.T. Simmons T. Melendy D. Usher Simian virus 40 large T antigen binds to topoisomerase I Virology 222 1996 365
83. J. Speyer H. Hochster C. Runowicz First line therapy of ovarian cancer with cisplatin and prolonged infusion topotecan Proceedings of the American Society of Clinical Oncology 34 1998 1352
84. Y. Sugimoto S. Tsukahara T. Oh-hara Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody Cancer Res 50 1990 6925
85. Y. Sugimoto S. Tsukahara T. Oh-hara Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines Cancer Res 50 1990 7962
86. T. Sugiyama K. Noda M. Yakushiji Multicenter phase II trial of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in recurrent or advanced cervical cancer: Japan CPT-11 study group trial Proceedings of the Annual Meeting of the American Society of Clinical Oncology 17 1998 A1360
87. T. Sugiyama S. Takeushi M. Yakushiji Phase I study of irinotecan (CPT-11) in combination with cisplatin (CDDP) on cervical carcinoma Proceedings of the Annual Meeting of the American Society of Clinical Oncology 13 1994 A856
88. T. Sugiyama T. Nishida A. Kataoka Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer Nippon Sanka Fujinka Gakkai Zasshi 48 1996 827
89. E.M. Swisher D.G. Mutch J.S. Rader Topotecan in platinum- and paclitaxel-resistant ovarian cancer Gynecol Oncol 66 1997 480
90. S. Takeuchi A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer Jpn J of Cancer and Chemoth 18 1991 1681
91. S. Takeuchi An early phase II study of CPT-11 for gynecologic cancer Jpn J Cancer Chemother 18 1991 579
92. K. Tamura M. Takada N. Masuda Radiosensitization effect of CPT-11 against human lung tumor xenografts Proceedings of the American Association for Cancer Research 36 1995 A605
93. A. Tanizawa R. Bertrand G. Kohlhagen Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance J Biol Chem 268 1993 25463
94. W. ten Bokkel Huinink M. Gore J. Carmichael Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 15 1997 2183
95. W.W. ten Bokkel Huinink D.J. Richel V.M.M. Herben Feasibility study of the combination of cisplatin, paclitaxel and topotecan in ovarian cancer patients Proceedings of the American Society of Clinical Oncology 34 1998 1353
96. T. Tsuruo T. Matsuzaki M. Matsushita Antitumor activity of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo Cancer Chemother Pharmacol 21 1988 71
97. P.A. Vasey N.A. Jones S. Jenkins Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance Mol Pharmacol 50 1996 1536
98. C. Verschraegen B. Giovanella K. Armstrong Phase II study of oral administration of 9-nitrocamptothecin in refractory ovarian cancer Proceedings of the American Society of Clinical Oncology 16 1997 A1356
99. C. Verschraegen N. Harris M. Steger Pharmacology study of multiple oral doses of 9-nitrocamptothecin (9NC) Proceedings of the American Association for Cancer Research 38 1997 A502
100. C.F. Verschraegen T. Levy A.P. Kudelka Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix J Clin Oncol 15 1997 625 631
101. C.F. Verschraegen E.A. Natelson B.C. Giovanella A Phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor Anticancer Drugs 9 1998 36
102. M.E. Wall M.C. Wani E.T. Cooke Plant antitumor agents. The isolation and structure of CPT, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata Journal of the American Chemical Society 88 1996 3888
103. M.I. Walton D. Whysong P.M. O'Connor Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis Cancer Res 53 1993 1853
104. J.C. Wang DNA topoisomerases Annu Rev Biochem 65 1996 635
105. M.C. Wani P.E. Ronman J.T. Lindley Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs J Med Chem 23 1980 554
106. M.C. Wani A.W. Nicholas G. Manikumar Plant antitumor agents. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations J Med Chem 30 1987 1774
107. M.C. Wani A.W. Nicholas M.E. Wall Plant antitumor agents. Synthesis and antileukemia activity of camptothecin analogs J Med Chem 29 1986 2358
108. P.M. Watt I.D. Hickson Failure to unwind causes cancer Curr Biol 6 1996 265
109. P.M. Watt E.J. Louis R.H. Borts Sgs1: A eukaryotic homolog of E. coli RecQ that interacts with topoisomerase II in vivo and is required for faithful chromosome segregation Cell 81 1995 253
110. C.M. Whitacre E. Zborowska N.H. Gordon Topotecan increases topoisomerase IIa levels and sensitivity to treatment with etoposide in a schedule-dependent process Cancer Res 57 1997 1425
111. R.D. Woessner W. Eng G.A. Hofmann Camptothecin hyperresistant P388 cells: Drug-dependent reduction in topoisomerase I content Oncol Res 4 1992 481
112. J. Wu L.F. Liu Processing of topoisomerase I cleavable complexes into DNA damage by transcription Nucleic Acids Res 25 1997 4181